Results 11 to 20 of about 49,152 (197)
Effectiveness of Pamidronate Infusion in the Treatment of Charcot Arthropathy [PDF]
Malaysian Orthopaedic JournalIntroduction: The objective of this case series is to investigate the efficacy and safety of intravenous infusion of Pamidronate, a second generation bisphosphonate, in the treatment of active Charcot arthropathy.
Bajuri MY +4 more
doaj +3 more sources
Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta [PDF]
Pediatrics and Neonatology, 2008 Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our experience using pamidronate in Taiwanese patients with OI.
Hsiang-Yu Lin +4 more
doaj +2 more sources
Intravenous pamidronate for refractory rheumatoid arthritis
Journal of Research in Medical Sciences, 2012 Background: Patients with rheumatoid arthritis may be resistant to conventional treatment with disease-modifying antirheumatic drugs (DMARDs). On the other hand, biologic therapy is costly and may be inconvenient for many patients.
Mansour Salesi +3 more
doaj +1 more source
Comparison of Calcitonin and Pamidronate Treatments in Children with Osteogenesis Imperfecta
Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2013 Purpose: The main objective of this study was to compare the treatments of calcitonin and pamidronate by clinical, biochemical, and radiological findings in children with osteogenesis imperfecta and evaluate the efficiency of pamidronate treatment ...
Neslihan Onenli Mungan +5 more
doaj +1 more source
Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
Journal of Research in Medical Sciences, 2011 Pamidronate is a bisphosphonate derivative that can inhibit bone resorption by actions on osteoclasts and increase bone density in spite of treatment with steroids. This drug has the anti-inflammatory effect by increase apoptosis of monocytes.
Mansour Salesi, Peyman Mottaghi
doaj +1 more source
Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
Therapeutics and Clinical Risk Management, 2008 Dimitrios Chantzichristos, Andréasson Björn, Johansson PeterDepartment of Internal Medicine, Uddevalla Hospital, Uddevalla, SwedenBackground: Once a month, patients with multiple myeloma received an infusion of bisphosphonates ...
Dimitrios Chantzichristos +2 more
doaj +1 more source
Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2021 Purpose Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment.
Ji-Hee Yoon +4 more
doaj +1 more source
BMC Musculoskeletal Disorders, 2009 Background In case of contraindications or intolerance during treatment with oral bisphosphonates (OB), administration of pamidronate intravenously is a widely used alternative. In this study we compared the effect on change in bone mineral density (BMD)
Dijkmans Ben AC +5 more
doaj +1 more source
The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy [PDF]
Korean Journal of Pediatrics, 2017 PurposeQuadriplegic children with cerebral palsy are more susceptible to osteoporosis because of various risk factors that interfere with bone metabolism. Pamidronate is effective for pediatric osteoporosis, but there are no guidelines for optimal dosage
Soon Jeong Moon +4 more
doaj +1 more source
Nephrotic syndrome induced by pamidronate [PDF]
, 2010 Contains fulltext : 97151.pdf (Publisher’s version ) (Open Access)Two patients developed nephrotic syndrome and progressive loss of renal function following treatment with i.v. pamidronate.
Wetzels, J.F.M. +5 more
core +1 more source